Click for best price
Specific Antiviral Drugs for COVID19 Market Size, Share 2023
This report contains market size and forecasts of Specific Antiviral Drugs for COVID-19 in Global, including the following market information:
Global Specific Antiviral Drugs for COVID-19 Market Size 2024-2035, ($ millions)
The global Specific Antiviral Drugs for COVID-19 market is projected to reach US$ million by 2035.
We surveyed the Specific Antiviral Drugs for COVID-19 companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Specific Antiviral Drugs for COVID-19 Market, by Type, 2024-2035 ($ millions)
Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, by Type
Tablet
Injection
Global Specific Antiviral Drugs for COVID-19 Market, by Application, 2024-2035 ($ millions)
Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, by Application
Mild Symptom Patient
Critically Ill Patient
Global Specific Antiviral Drugs for COVID-19 Market, By Region and Country, 2024-2035 ($ Millions)
Global Specific Antiviral Drugs for COVID-19 Market Segment Percentages, by region and country
United States
Europe
Asia
China
Rest of World
Competitor Analysis
The report also provides analysis of leading market participants including:
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
| Report Attributes |
Report Details |
| Report Title |
Specific Antiviral Drugs for COVID-19 Market, Global Outlook and Forecast 2023-2035 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Specific Antiviral Drugs for COVID-19 Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Specific Antiviral Drugs for COVID-19 Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Specific Antiviral Drugs for COVID-19 Overall Market Size
2.1 Global Specific Antiviral Drugs for COVID-19 Market Size: 2023 VS 2035
2.2 Global Specific Antiviral Drugs for COVID-19 Market Size, Prospects & Forecasts: 2023-2035
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Key Specific Antiviral Drugs for COVID-19 Players in Global Market
3.2 Global Companies Specific Antiviral Drugs for COVID-19 Product & Technology
4 Specific Antiviral Drugs for COVID-19 Companies Profiles
4.1 Sanofi
4.1.1 Sanofi Company Summary
4.1.2 Sanofi Business Overview
4.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.1.4 Sanofi Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.2 Novartis
4.2.1 Novartis Company Summary
4.2.2 Novartis Business Overview
4.2.3 Novartis Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.2.4 Novartis Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.3 Shanghai Zhongxisanwei
4.3.1 Shanghai Zhongxisanwei Company Summary
4.3.2 Shanghai Zhongxisanwei Business Overview
4.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.3.4 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.4 Teva
4.4.1 Teva Company Summary
4.4.2 Teva Business Overview
4.4.3 Teva Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.4.4 Teva Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.5 Zydus Cadila
4.5.1 Zydus Cadila Company Summary
4.5.2 Zydus Cadila Business Overview
4.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.5.4 Zydus Cadila Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.6 Mylan
4.6.1 Mylan Company Summary
4.6.2 Mylan Business Overview
4.6.3 Mylan Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.6.4 Mylan Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.7 Apotex
4.7.1 Apotex Company Summary
4.7.2 Apotex Business Overview
4.7.3 Apotex Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.7.4 Apotex Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.8 Advanz Pharma
4.8.1 Advanz Pharma Company Summary
4.8.2 Advanz Pharma Business Overview
4.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.8.4 Advanz Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.9 Sun Pharma
4.9.1 Sun Pharma Company Summary
4.9.2 Sun Pharma Business Overview
4.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.9.4 Sun Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.10 Kyung Poong
4.10.1 Kyung Poong Company Summary
4.10.2 Kyung Poong Business Overview
4.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.10.4 Kyung Poong Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.11 Ipca Laboratories
4.11.1 Ipca Laboratories Company Summary
4.11.2 Ipca Laboratories Business Overview
4.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.11.4 Ipca Laboratories Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.12 Hanlim Pharmaceutical
4.12.1 Hanlim Pharmaceutical Company Summary
4.12.2 Hanlim Pharmaceutical Business Overview
4.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.12.4 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.13 Bristol Laboratories
4.13.1 Bristol Laboratories Company Summary
4.13.2 Bristol Laboratories Business Overview
4.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.13.4 Bristol Laboratories Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.14 Bayer
4.14.1 Bayer Company Summary
4.14.2 Bayer Business Overview
4.14.3 Bayer Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.14.4 Bayer Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.15 Rising Pharmaceutical
4.15.1 Rising Pharmaceutical Company Summary
4.15.2 Rising Pharmaceutical Business Overview
4.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.15.4 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.16 Shanghai Pharma
4.16.1 Shanghai Pharma Company Summary
4.16.2 Shanghai Pharma Business Overview
4.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.16.4 Shanghai Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.17 Sichuan Sunny Hope
4.17.1 Sichuan Sunny Hope Company Summary
4.17.2 Sichuan Sunny Hope Business Overview
4.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.17.4 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
4.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Summary
4.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
4.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.19 CSPC Group
4.19.1 CSPC Group Company Summary
4.19.2 CSPC Group Business Overview
4.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.19.4 CSPC Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.20 KPC Group
4.20.1 KPC Group Company Summary
4.20.2 KPC Group Business Overview
4.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.20.4 KPC Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.21 Jinghua Pharmaceutical Group
4.21.1 Jinghua Pharmaceutical Group Company Summary
4.21.2 Jinghua Pharmaceutical Group Business Overview
4.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.21.4 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.22 Zhongsheng Pharma
4.22.1 Zhongsheng Pharma Company Summary
4.22.2 Zhongsheng Pharma Business Overview
4.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.22.4 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 R&D, and Plans
4.23 North China Pharmaceutical Group
4.23.1 North China Pharmaceutical Group Company Summary
4.23.2 North China Pharmaceutical Group Business Overview
4.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings & Technology
4.23.4 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 R&D, and Plans
5 Sights by Region
5.1 By Region - Global Specific Antiviral Drugs for COVID-19 Market Size, 2024 & 2035
5.2 By Region - Global Specific Antiviral Drugs for COVID-19 Revenue, (2024-2035)
5.3 United States
5.3.1 Key Players of Specific Antiviral Drugs for COVID-19 in United States
5.3.2 United States Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.4 Europe
5.4.1 Key Players of Specific Antiviral Drugs for COVID-19 in Europe
5.4.2 Europe Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.5 China
5.5.1 Key Players of Specific Antiviral Drugs for COVID-19 in China
5.5.2 China Specific Antiviral Drugs for COVID-19 Development Current Situation and Forecast
5.6 Rest of World
6 Sights by Product
6.1 By Type - Global Specific Antiviral Drugs for COVID-19 Market Size Markets, 2024 & 2035
6.2 Tablet
6.3 Injection
7 Sights by Application
7.1 By Application - Global Specific Antiviral Drugs for COVID-19 Market Size, 2024 & 2035
7.2 Mild Symptom Patient
7.3 Critically Ill Patient
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Specific Antiviral Drugs for COVID-19 Market Opportunities & Trends in Global Market
Table 2. Specific Antiviral Drugs for COVID-19 Market Drivers in Global Market
Table 3. Specific Antiviral Drugs for COVID-19 Market Restraints in Global Market
Table 4. Key Players of Specific Antiviral Drugs for COVID-19 in Global Market
Table 5. Global Companies Specific Antiviral Drugs for COVID-19 Product & Technology
Table 6. Sanofi Company Summary
Table 7. Sanofi Specific Antiviral Drugs for COVID-19 Product Offerings
Table 8. Novartis Company Summary
Table 9. Novartis Specific Antiviral Drugs for COVID-19 Product Offerings
Table 10. Shanghai Zhongxisanwei Company Summary
Table 11. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product Offerings
Table 12. Teva Company Summary
Table 13. Teva Specific Antiviral Drugs for COVID-19 Product Offerings
Table 14. Zydus Cadila Company Summary
Table 15. Zydus Cadila Specific Antiviral Drugs for COVID-19 Product Offerings
Table 16. Mylan Company Summary
Table 17. Mylan Specific Antiviral Drugs for COVID-19 Product Offerings
Table 18. Apotex Company Summary
Table 19. Apotex Specific Antiviral Drugs for COVID-19 Product Offerings
Table 20. Advanz Pharma Company Summary
Table 21. Advanz Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 22. Sun Pharma Company Summary
Table 23. Sun Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 24. Kyung Poong Company Summary
Table 25. Kyung Poong Specific Antiviral Drugs for COVID-19 Product Offerings
Table 26. Ipca Laboratories Company Summary
Table 27. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings
Table 28. Hanlim Pharmaceutical Company Summary
Table 29. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 30. Bristol Laboratories Company Summary
Table 31. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product Offerings
Table 32. Bayer Company Summary
Table 33. Bayer Specific Antiviral Drugs for COVID-19 Product Offerings
Table 34. Rising Pharmaceutical Company Summary
Table 35. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 36. Shanghai Pharma Company Summary
Table 37. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 38. Sichuan Sunny Hope Company Summary
Table 39. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product Offerings
Table 40. Guangzhou Baiyunshan Guanghua Pharmaceutical Company Summary
Table 41. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Offerings
Table 42. CSPC Group Company Summary
Table 43. CSPC Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 44. KPC Group Company Summary
Table 45. KPC Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 46. Jinghua Pharmaceutical Group Company Summary
Table 47. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 48. Zhongsheng Pharma Company Summary
Table 49. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product Offerings
Table 50. North China Pharmaceutical Group Company Summary
Table 51. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Offerings
Table 52. By Region? Global Specific Antiviral Drugs for COVID-19 Revenue, (US$, Mn), 2024 & 2035
Table 53. By Region - Global Specific Antiviral Drugs for COVID-19 Revenue, (US$, Mn), 2024-2035
Table 54. By Type ? Global Specific Antiviral Drugs for COVID-19 Market Size, (US$, Mn), 2024 & 2035
Table 55. By Application? Global Specific Antiviral Drugs for COVID-19 Market Size, (US$, Mn), 2024 & 2035
List of Figures
Figure 1. Specific Antiviral Drugs for COVID-19 Segment by Type in 2035
Figure 2. Specific Antiviral Drugs for COVID-19 Segment by Application in 2035
Figure 3. Global Specific Antiviral Drugs for COVID-19 Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Specific Antiviral Drugs for COVID-19 Market Size: 2023 VS 2035 (US$, Mn)
Figure 6. Global Specific Antiviral Drugs for COVID-19 Revenue, 2017-2028 (US$, Mn)
Figure 7. By Region - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2024-2035
Figure 8. By Type - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2024-2035
Figure 9. By Application - Global Specific Antiviral Drugs for COVID-19 Revenue Market Share, 2024-2035
